The election of Donald Trump isn’t going to bring an end to scrutiny of healthcare mergers, like the high-profile cases against giant health insurers Aetna AET  and Humana or Anthem WLP  and Cigna.

A trial begins Monday in U.S. District Court in Washington, D.C., pitting the U.S. Justice Department against Anthem and Cigna, challenging Anthem’s $53 billion acquisition to create a national health insurance powerhouse. And next month, the federal government’s challenge of Aetna’s $37 billion takeover of Humana goes to trial Dec. 5.

The cases were brought by the U.S. Justice Department, led by Attorney General Loretta Lynch, who was appointed by President Barack Obama, a Democrat. On the day the lawsuits were announced last July, Lynch’s team said the deals would thwart competition, raises prices and hurt the quality of patient care.

 But don’t expect any change in policy toward potential monopolies in healthcare from a Justice Department or Federal Trade Commission that will soon be led by political appointees of Republican President Trump.

“Federal antitrust litigation is clearly a nonpartisan sport,” says antitrust attorney David Balto , a former policy director at the Federal Trade Commission who has also been critical of the parade of health plan mergers. “As millions contemplate the meaning of the election of Donald Trump as our 45th President, some might speculate this may lead to the demise of the Justice Department’s challenges to the Aetna-Humana and Anthem-Cigna mergers. They could not be more wrong.”

Click to Read More